在乳腺癌中,APOBEC3突变驱动治疗耐药性
bioRxiv : the preprint server for biology
|May 15, 2024
概括
阿波利波蛋白B mRNA编辑酶催化多类3 (APOBEC3) 酶驱动转移性乳腺癌的治疗耐药性. 这项研究揭示了APOBEC3突变发生是治疗耐药性的关键因素,也是潜在的治疗标.
科学领域:
- 基因组学就是基因组学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 获得的遗传变异是转移性乳腺癌中治疗耐药性的主要原因.
- 驱动这些变化的特定突变过程在很大程度上是未知的.
研究的目的:
- 为了识别乳腺癌中的突变过程.
- 研究这些过程对临床结果和治疗耐药性的影响.
主要方法:
- 分析了3880名转移性乳腺癌患者的结对瘤-正常测序数据.
- 乳腺癌模型和初级转移样本的全基因组测序 (WGS).
- 对阿波利波蛋白B mRNA编辑酶催化型多类3 (APOBEC3) 突变特征的评估.
主要成果:
- 在治疗后,APOBEC3突变特征比未经治疗的激素受体阳性 (HR+) 癌症更为普遍.
- 在HR+转移性乳腺癌患者中,APOBEC3签名与较短的无进展生存时间有关,这些患者接受了抗雌激素加CDK4/6抑制剂治疗.
- 活性APOBEC3突变被证明通过RB1功能丧失突变等变化促进对内分泌和向疗法的耐药性.
结论:
- 在乳腺癌中,APOBEC3突变是治疗耐药性的常见驱动因素.
- 即使在治疗前,APOBEC3活动在乳腺癌的演变中发挥着普遍作用.
- APOBEC3可以作为一种生物标志物和治疗点来克服治疗耐药性.
更多相关视频
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.3K
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.6K
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mutagenicity and Carcinogenicity
1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mismatch Repair
4.8K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
